Please login to the form below

Not currently logged in
Email:
Password:

Pearl Therapeutics

This page shows the latest Pearl Therapeutics news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca scores in final lung disease drug trials

AstraZeneca scores in final lung disease drug trials

It is also the first LAMA/LABA combination to be delivered in a pressurised metered dose inhaler (pMDI) using the unique porous particle co-suspension technology developed by Pearl Therapeutics, which

Latest news

  • AZ's new COPD therapy gets green light in Europe AZ's new COPD therapy gets green light in Europe

    PT010 which combines formoterol, another LAMA called glycopyrrolate and an inhaled corticosteroid that was acquired along with Pearl Therapeutics last year.

  • AZ licenses asthma infection drug from Synairgen AZ licenses asthma infection drug from Synairgen

    Leading its respiratory pipeline at the moment is long-acting muscarinic antagonist (LAMA) PT001 - which was licensed from Pearl Therapeutics last year in a deal worth up to $1.15bn that

  • Teva's Symbicort generic backed for EU approval Teva's Symbicort generic backed for EU approval

    AZ is developing a new generation of respiratory drugs to try to maintain its position in the respiratory category, including COPD combination therapy PT003 (glycopyrrolate and formoterol fumarate), acquired with Pearl ... Therapeutics last year.

  • Soriot says pipeline will speed recovery at AZ Soriot says pipeline will speed recovery at AZ

    Last year it bought respiratory company Pearl Therapeutics in a $1.15bn deal as well as biopharma companies AlphaCore Pharma, Spirogen, Amplimmune and Omthera Pharmaceuticals.

  • 2013 - biotech boomed 2013 - biotech boomed

    Its biotech haul included AlphaCore Pharma, a US company developing a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme with potential in cardiovascular disease and respiratory specialist Pearl Therapeutics, which has a

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).

  • Pharma deals during June 2013 Pharma deals during June 2013

    Respiratory acquisitions. Continuing its run of deal activities, AstraZeneca (AZ) built on its respiratory interests with the acquisition of Pearl Therapeutics at a headline value of $1.15bn. ... AZ paid an initial $560m for Pearl's shares and a deferred

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Kala names Howard Rosen as chairman Kala names Howard Rosen as chairman

    Kala names Howard Rosen as chairman. He is former CEO of Pearl Therapeutics and VP at Gilead. ... His non-board experience includes serving as president and CEO of Pearl Therapeutics, which was acquired by AstraZeneca last year in a deal worth up to

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics